PTGX

Protagonist Therapeutics, Inc.

32.63 USD
+0.04 (+0.12%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Protagonist Therapeutics, Inc. stock is up 4.38% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 7 June’s closed higher than May. In the last 2 Unusual Options Trades, there were 2 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
20 May 18:01 19 Jul, 2024 25.00 CALL 78 204
07 Jun 16:53 21 Jun, 2024 35.00 CALL 250 19

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.

  • JP Morgan
    Mon Jun 17, 08:19
    buy
    confirm
  • HC Wainwright & Co.
    Fri Jun 14, 13:09
    buy
    confirm